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Abstract
Background: More than 100,000 chemicals are in use but have not been tested for their safety. To overcome limitations in
the cancer bioassay several alternative testing strategies are explored. The inability to monitor non-invasively onset and
progression of disease limits, however, the value of current testing strategies. Here, we report the application of in vivo
imaging to a c-Myc transgenic mouse model of liver cancer for the development of a short-term cancer bioassay.
Methodology/Principal Findings: mCT and
18F-FDG mPET were used to detect and quantify tumor lesions after treatment
with the genotoxic carcinogen NDEA, the tumor promoting agent BHT or the hepatotoxin paracetamol. Tumor growth was
investigated between the ages of 4 to 8.5 months and contrast-enhanced mCT imaging detected liver lesions as well as
metastatic spread with high sensitivity and accuracy as confirmed by histopathology. Significant differences in the onset of
tumor growth, tumor load and glucose metabolism were observed when the NDEA treatment group was compared with
any of the other treatment groups. NDEA treatment of c-Myc transgenic mice significantly accelerated tumor growth and
caused metastatic spread of HCC in to lung but this treatment also induced primary lung cancer growth. In contrast, BHT
and paracetamol did not promote hepatocarcinogenesis.
Conclusions/Significance: The present study evidences the accuracy of in vivo imaging in defining tumor growth, tumor
load, lesion number and metastatic spread. Consequently, the application of in vivo imaging techniques to transgenic
animal models may possibly enable short-term cancer bioassays to significantly improve hazard identification and follow-up
examinations of different organs by non-invasive methods.
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Introduction
Hepatocellular carcinoma (HCC) is frequently observed in
cancer bioassays as a result of lifetime exposure to either
experimental drugs or a diverse range of chemicals. Specifically,
carcinogens can be distinguished by their mode of action some of
which exert activity either through DNA damage and thus are
defined as genotoxic carcinogens such as N-nitrosodiethylamine
(NDEA), while others do not harm DNA but cause perturbations
in biological process that ultimately leads to uncontrolled growth
and are termed non-genotoxic carcinogens. This latter group of
carcinogens is inherently more difficult to predict. Furthermore,
drugs and chemicals may not be by themselves tumorigenic but
promote tumor growth.
Furthermore, while the process of evaluating the safety of
chemicals is internationally harmonized, it remains costly and time
consuming. In order to reduce the time needed for an evaluation
of the carcinogenic risk of drugs and chemicals, novel transgenic
animal models have been developed and biological read outs from
such models are compared to the established cancer bioassay.
However, the common cancer bioassays require an observation
period of 2 years and utilize a large number of animals that are
subsequently subjected to histopathology examinations [1].
To overcome limitations in the cancer bioassay several
alternative testing strategies are being explored, either involving
genetically modified animals, in vitro cell based assays or
computerized models [2–7]. In this regard genetically modified
laboratory animals may prove valuable in the early detection of
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2liver carcinogens and thus may enable short-term carcinogenicity
studies. So far, several knock-out models as well as transgenic
mouse models of hepatocellular carcinoma have been reported
[8]. For example the response to the genotoxic carcinogen NDEA
was evaluated in a p53-deficient [9] as well as in the rasH2
transgenic model [10–12]. Unfortunately, both models failed to
identify NDEA as a liver carcinogen in short-term cancer
bioassays rendering this strategy less robust for the detection of
organ specific carcinogens with these two genetic models.
Additionally, the standard rodent carcinogenicity assays is
unable to monitor non-invasively onset and progression of disease.
Hence, imaging techniques like micro computed tomography
(mCT) and micro positron emission tomography (mPET) may
become a method of choice in preclinical studies to detect in vivo
tumor lesions and to quantify tumor load. In vivo imaging will thus
contribute to the refinement of cancer bioassays and offer
additional information, such as an identification of metastatic
spread and secondary tumor growth in a timely fashion [13].
Indeed, the recent advancement in small animal imaging
technologies encouraged us to examine the utility of mCT and
mPET for the detection of tumor lesions in a transgenic mouse
model of liver cancer. With such enabling technologies mCT
delivers a resolution of anatomical structures of about 50 mm,
therefore providing considerable morphological information. This
requires, however, the use of an organ specific contrast agent to
allow imaging of the parenchymatous morphology. Notably, the c-
Myc transgenic mouse model efficiently develops liver cancer in a
short period of time. In this genetic model, c-Myc is targeted to the
liver by use of the a1-antitrypsine promoter which is exclusively
activated in the liver. This model was originally developed by
Dalemans et al. [14], but has not been explored for its usefulness in
short-term cancer bioassays, as yet. Notably, human molecular
pathology studies identified c-Myc as hyperactive and overex-
pressed in the majority of human hepatocellular carcinoma [15]
therefore providing a rational for an evaluation of this disease
model.
While a few reports describe the application of anatomical and
metabolic imaging of primary liver malignancies in rodents [16–
19], the aim of this study was firstly, to develop strategies and
define parameters for the detection and the quantification of liver
lesions by in vivo contrast-enhanced mCT and
18F-FDG mPET
metabolic imaging of glucose uptake and secondly, to evaluate the
accuracy of these methods when compared with histopathology
and thirdly, to determine the utility of the c-Myc transgenic mouse
model in accurately predicting the liver carcinogen NDEA in
short-term bioassay and thus to evaluate whether a combination of
in vivo imaging modalities and the use of genetic mouse models
may help to develop short-term cancer bioassays for the early
detection of hazardous drugs and chemicals.
Materials and Methods
Transgenic tumor model
All animal work followed strictly the Public Health Service
Policy on the humane care and use of laboratory animals.
Permission to carry out the study was obtained by the animal
welfare ethics committee of the city of Hannover, Germany
(Tierversuchsvorhaben 33.9-42502-04-08/1619).
c-Myc transgenic mice were the kind gift of Dalemans et al.
[14]. The animals were maintained as homozygotes in the C57/
Bl6 background and this background is widely used in transgenic
disease models such as the rasH2 and p53 deficient model.
Notably the transgene (see Figure S1) consists of the c-Myc open
reading frame and regulatory sequences of the a1-antitrypsine
promoter to allow liver specific gene expression of c-Myc. This
genetic disease model has an incidence of liver cancer of 100%.
The transgene was detected by PCR using the forward primer:
59-CACTGCGAGGGGTTCTGGAGAGGC-39 and the reverse
primer: 59-ATCGTCGTGGCTGTCTGCTGG-39. The follow-
ing PCR assay conditions were used: 15 min, 95uC, 1 min 60uC,
1 min 70uC, 1 min 95uC, 31 cycles.
Altogether 120 c-Myc transgenic mice were examined by in vivo
imaging and/or histopathology, while the non-transgenic controls
were studied by histopathology only, as these animals do not have
tumors. Mice were kept as groups of animals with 1 to 4 mice per
cage on sawdust in a 12 hour light-dark cycle, and 50% relative
humidity and an ambient temperature of 22uC. The animals
received standardized chow and drinking water ad libitum (Zucht,
ssniff M-/, 10 mm, complete diet for mice, ssniff Specifications
GmbH, DE-59494, www.ssniff.de).
Study design and treatment of animals with NDEA,
Butylated Hydroxy Toluene (BHT) and paracetamol
The animals were divided into 7 groups of 24 animals each and
consisted of n=12 males and n=12 females. Treatment of
transgenic mice with intraperitoneal injection of NDEA, BHT or
paracetemol (Sigma Aldrich, Germany with a purity of .99%),
was started at the age of 2 months. The transgenic and the non-
transgenic control animals were also treated with the vehicle only,
i.e. corn oil or physiological saline (Sigma Aldrich, Germany).
NDEA mice were treated once a week by injection of 75 mg/g
NDEA in saline over a period of 6 weeks while animals receiving
300 mg/g BHT in corn oil were treated once a week for 8 weeks.
Moreover, 100 mg/g paracetamol in saline served as a non-
carcinogenic hepatotoxin, and this drug was given once daily for 5
days per week over a period of 8 weeks (see Table 1 for the dosing
regime).
As C57Bl/6 mice are resistant to hepatocarcinogenesis induced
by NDEA [9] a non-transgenic NDEA and BHT treatment group
was not included in the study design It is of considerable interest
that a similar lack of sensitivity was reported for p53 deficient and
for rasH2/CB6F1 transgenic mice which were bred in the same
C57BL/6 background [11]. Likewise, it was shown earlier that
BHT enhances tumor formation only if administered after
exposure to the genotoxic agent urethane, but has no effect on
its one [20] or is even protective, if given before a carcinogen
[21,22]. A summary of the treatment schedule is given in Table 1.
Dose selection
Based on previously published data, where different doses of
NDEA were investigated (dose range 75 to 200 mg/g) to cause
tumor formation in non-transgenic rodents [23,24,25,26], a dose
of 75 mg/g body weight was selected and given once weekly for 6
weeks by intraperitoneal administration. In the case of BHT a dose
of 300 mg/g bodyweight was administered. This dose was reported
to cause tumor induction in the liver [20]. Finally, paracetamol
served as the non-carcinogenic hepatotoxin and a dose of 100 mg/
g bodyweight was given i.p. once daily for 5 days per week over a
period of 8 weeks
In vivo imaging of transgenic animals by mCT and mPET
At four different time points – i.e. at the age of 4, 5.5, 7 and 8.5
months - in vivo mCT and mPET imaging were employed; animals
were sacrificed afterwards for histopathology.
All imaging procedures were performed under inhalation
anesthesia with isoflurane (Isoba vet., Essex Pharma, Germany)
at a concentration of 4% for induction of anesthesia and 1–2% for
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temperature controlled bed at 39uC (T/Pump, Gaymar, Orchard
Park, NY, USA) allowing changes between imaging modalities
without repositioning and isoflurane was supplied via a nose cone
(Summit Anesthesia Solutions, Bend, OR, USA). The animal
respiration was spontaneous, and the breathing was monitored
continuously using a small pressure transducer (Biovet, m2m
imaging, Newark, NJ, USA). Breathing was maintained at a rate
between 60 and 100 per minute. After image data acquisition the
recovery time of the animals from anaesthesia was usually less than
five minutes. Overall the procedures were well tolerated.
Specifically, sequential mCT and
18F-FDG mPET imaging were
carried out with a total of 60 animals as shown in Table 1. Mice
were imaged at the age of 4 (1st sacrifice), 5.5 (2nd sacrifice), 7 (3rd
sacrifice) and 8.5 months (4th sacrifice). The transgenic control
animals were examined at the age of 8.5 months only (4th
sacrifice), although some explorative contrast-enhanced imaging
was carried out at the age of 2, 5 and 7 months. All animals were
sacrificed 2 days after the PET imaging. At this time the
radioactive tracer declined to below the level of detection. Imaging
findings were corroborated by standard histopathology as detailed
below.
Contrast enhanced mCT imaging
All animals were fasted prior to imaging for about 6 hours.
Three hours prior to CT scans anaesthetized mice were given an
intravenous injection of a liver-specific iodinated contrast agent
(DHOG, Fenestra LC, ART Inc., Saint-Laurent, Canada) at an
approximately volume of 200–300 ml (10 ml/g bodyweight) into
the tail vein. The image data acquisition was carried out as
recommended by the manufacturer and previously published
protocols [18,19].
The mCT scan was done with a high-resolution small animal
computed tomography scanner (eXplore Locus, GE Healthcare,
Chalfont St. Giles, UK). The scan parameters were set as follow:
tube voltage 80 kVp, tube current 450 mA, number of acquisition
360, number of views 720, exposure time 100 ms, one average per
frame, axial field-of-view 33 mm. Scans were recorded without
respiratory gating. Total scan duration was about 12 minutes.
Image data was reconstructed using a cone-beam algorithm on
an 8-node linux cluster. The resulting voxel size of the isotropic
dataset was 45 mm. Arbitrary attenuation values were converted to
the Hounsfield scale using a calibration phantom with water, air
and bone inserts.
mPET imaging
Anaesthetized mice were given an intraperitoneal injection (i.p.)
of 10 MBq (
18F)-2-fluoro-2-deoxyglucose in a total volume of 50–
100 ml sterile isotonic saline solution supplied by the Department
of Nuclear Medicine, Hannover Medical School, Germany.
Animals were subjected to sequential CT and PET imaging
which necessitated multiple injections into the tail vein to possible
cause vascular lesions and embolization at the injection site. As CT
scans required i.v. administration of Fenestra (see above)
18F-FDG
was given by i.p. injection. This may delay standard acquisition of
FDG, however, did not influence the overall interpretation of data
with glucose uptake being proportional to tumor growth as
evidenced in the present study. Therefore, after CT image
acquisitions
18F-FDG was administered to mice by i.p. injection.
The animals remained anesthetized and after about 35 min were
transferred on the same bed/position from the CT scanner to the
PET scanner. Static images were acquired exactly after 45 min-
utes of injection of the tracer using a high-resolution small animal
PET camera (eXplore Vista, GE Healthcare, Chalfont St. Giles,
UK). Total acquisition time was 30 minutes for a single bed
position. Images were corrected for random events and scatter
prior to reconstruction with a 3D-FORE/2D-OSEM iterative
algorithm. No attenuation correction was used.
Image analysis
mCT datasets were visualized and analyzed using the software
packages Microview 2.2 (GE Healthcare, Chalfont St. Diles, UK),
MeVisLab 2.0 (MeVis Medical Solutions AG, Bremen, Germany)
and OsiriX (v.3.7.1 32-bit, Pixmeo Sarl). Total liver volume was
calculated using the LiveWireMacro module (MeVisLab 2.0)
which utilizes a contour-based semi-automatic segmentation
method. Focal liver lesions were counted and quantified by 2D-
measurement of the largest diameter. The diameter (d) of the
lesions was used to estimated the tumor volume by the following
formula: tumor volume (V)=1/66p6d
3. The volumes of all liver
lesions were added to determine the total tumor volume. The
tumor percentage of the liver was calculated as the ratio of the
total tumor volume (ml) and the total liver volume (ml).
Rigid registration of PET and CT datasets was based on
anatomical landmarks and used to generate fused datasets.
Regions-of-interest (ROI) were manually defined for focal liver
lesions of a diameter above 5 mm as detected in mCT and
18F-
FDG mPET imaging. The background (non-tumor) signal was
determined by placing a ROI in the tumor-free liver parenchyma
Table 1. Study groups and imaging protocol.
Animals Treatment (vehicle) Dose (duration)
Age at which CT/PET examination and
histopathology was done
1 transgenic NDEA (0.9% NaCl) 75 mg/g (once weekly for 6w) 4 m 5.5 m 7 m 8.5 m
2 transgenic BHT (corn oil) 300 mg/g (once weekly for 8w) 4 m 5.5 m 7 m 8.5 m
3 transgenic paracetamol (0.9% NaCl) 100 mg/g (5 days per week for 8w) 4 m 5.5 m 7 m 8.5 m*
4 transgenic - (0.9% NaCl) (once weekly for 6w) 4 m 5.5 m 7 m 8.5 m**
5 transgenic - (corn oil) (once weekly for 8w) 4 m 5.5 m 7 m 8.5 m**
6 non-transgenic - (0.9% NaCl) (once weekly for 6w) 4 m 5.5 m 7 m 8.5 m*
7 non-transgenic - (corn oil) (once weekly for 8w) 4 m 5.5 m 7 m 8.5 m*
Histopathology was carried out for all groups and for all time points (4, 5.5, 7, 8.5 months).
*No CT/PET imaging was done,
**CT/PET was acquired at the age of 8.5 months only. m, months; w, weeks.
doi:10.1371/journal.pone.0030432.t001
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ROI to estimate the tumor-to-non-tumor ratios.
Histopathology
Two days after the last imaging mice were euthanized and liver
and lung were removed for histopathology. The entire lungs and
livers were immersed in buffered 4% formaldehyde and embedded
in paraffin by standard laboratory procedures. Subsequently, 4–
5 mm sections of the blocks spaced at an interval of 500 mm were
prepared from the central core of the embedded tissue and stained
with H&E. These slides were examined using an Olympus BX51
microscope at a 406 original magnification. 4 different morpho-
logical findings were recorded: 1) regular hepatic parenchyma as
defined by cell size and preservation of architecture, 2) diffuse toxic
injury of the liver parenchyma as defined by ballooning,
degeneration, but preservation of architecture, 3) dysplastic nodules
with nodular aggregates of enlarged liver cells with low grade
cellular dysplasia, 4) hepatocellular carcinoma as defined by cellular
and architectural atypia with multilayered trabecular or pseudog-
lands. Type, number and size were recorded for all lesions and
compared with the results of the radiological imaging. Furthermore,
the tumor load was scored semiquantitatively using 5% increments.
Statistical analysis
The in vivo imaged liver volume and the ex vivo measured liver
weight were recorded and the liver volume and the tumor volume
were computed and defined as the tumor percentage. All values
are given as mean6SEM. Statistical significance was determined
by the Pearson correlation test (r is the correlation coefficient) and
imaging findings were validated by histopathology as described
above.
The tumor-to-non-tumor ratios were defined for small
(,5 mm), medium (5–10 mm) and large lesions (.10 mm) and
statistical significant differences were determined using the one-
way ANOVA and the Bonferroni post-test.
At different time points and for all study groups the means and
standard deviations of the tumor percentage, the tumor multiplic-
ity and the tumor-to-non-tumor ratio were compared. The one-
way ANOVA and the Bonferroni post test were used to evaluate
statistical significance (p-value cutoff determined as 0.05).
All statistical analyses were performed and visualized using
SPSS Statistics 17.0 and GraphPad Prism 5.0 (GraphPad
Software, Inc.).
Results
Contrast-enhanced liver morphology and glucose
metabolic imaging
At the beginning of the study none of the transgenic animals
had liver tumors or precursor lesions while at the end of the study
a total of 244 liver lesions were detected that varied in size between
0.9 mm and 25.0 mm. Notably, intravenous injection of the liver-
specific iodinated contrast agent DHOG defined tumor lesions as
hypodense as compared to the normal surrounding liver
parenchyma (Figure 1). Lesions of a size of .1 mm could be
identified with certainty by mCT but not with FDG mPET imaging
for lesions of ,5 mm. In animals with a high tumor load
individual lesions could not always be resolved due to individual
tumors that had merged together (collision tumors).
Assessment of growth and multiplicity of tumor lesions
Treatment of transgenic mice with the genotoxic hepatocarcin-
ogen NDEA induced rapidly the development of HCC. At the age
of 4 months (1st sacrifice) 1 out of 6 animals had HCC, and the
tumor incidence was already 100% at the age of 5.5 months (2nd
sacrifice). By CT imaging the liver and tumor volume was
determined and the resultant ratio was defined as tumor
percentage (Figure 2A). Overall, there was no difference in tumor
incidence or tumor volume when male and female c-myc
transgenic mice treated with NDEA were compared (Table 2).
The data was validated by histopathology as detailed below.
There was good agreement between the histopathology and in vivo
imaging results. With regard to tumor growth the greatest
difference was observed between the 1st and 2nd sacrifice where
CT-scans defined percentage tumor volumes of 2.8% and 58.0%,
respectively. At the age of 8.5 months (4th sacrifice) the percentage
tumor volume was 69.3%. The diameter and the numbers of
lesions were determined by CT imaging and by histopathology.
With NDEA the tumor lesions increased time dependently from
2.260.3 mm (1st sacrifice) to 6.560.9 mm (Figure 2B). Likewise,
tumor multiplicity for NDEA treated animals increased from the
first to 2nd sacrifice but decreased afterwards possibly as a result of
merging tumors (Figure 2C).
The time dependent tumor growth is also depicted in Figure 3,
where CT and PET scans of NDEA treated animals were acquired
at the age of 5.5 and 7 months, respectively. Here the glucose
metabolism in liver lesions was determined by in vivo
18F-FDG
mPET imaging.
To allow for accurate anatomical localization of focal
18F-FDG
uptake, registration and fusion of mCT and mPET datasets were
acquired prior to quantitative analysis of glucose imaging (see
Figure 3). For this purpose the animals were placed in prone
position on a multimodality temperature controlled bed without
repositioning of animals when imaging modalities were changed.
Thus, animals were kept under inhalation anesthesia and in the
same bed position between CT and PET scan to allow registration
of scans.
The
18F-FDG-uptake was mainly homogenous amongst the
liver lesions. Some larger lesions displayed an inhomogeneous
uptake of
18F-FDG that was particularly prominent in the
peripheral parts of the tumor. Inhomogeneous tracer uptake was
associated with cystic and necrotic changes of the tumor adjacent
to vital tumor tissue as evidenced by histopathology.
In general, the mean tumor-to-non-tumor ratio was dependent
on the tumor size (Figure 4). For lesions larger than 10 mm the
tumor-to-non-tumor ratio was 3.360.6 and determined to be
statistically significantly increased (p,0.05) when compared to
lesions with a diameter of 5 to 10 mm (1.660.2). For smaller
lesions the tumor-to-non-tumor ratio was 0.9860.03, therefore
suggesting no increase in
18F-FDG-uptake when compared to the
normal liver parenchyma.
Figure 5 summarizes PET/CT imaging and modality fusion of
images obtained from transgenic mice treated with either saline
(Figure 5A), BHT (Figure 5B) or NDEA (Figure 5C). Note, in 1 out
of the 6 animals treated with BHT a tumor of .10 mm was
observed.
Moreover, treatment of transgenic animals with the hepatotoxin
paracetamol did not induce tumor growth as determined by
histopathology (see below).
Validation of imaging results by histopathology
Histopathology evidenced normal liver with complete preser-
vation of lobular architecture, bile ducts and vasculature
parenchyma in non-transgenic mice. In vehicle treated c-Myc
transgenic animals diffuse dysplasia was observed (Figure 6A). A
small number of transgenic animals receiving either physiological
saline (1/24 animals) or corn oil (4/24 animals) as well as the BHT
treated animals (3/24 animals) displayed uni- or multifocal
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that ranged in size between 1 and 10 mm. These foci consisted of
enlarged hepatocytes with a preserved nuclear cytoplasmic ratio,
uni- to bicellular layers and an overall nodular architecture.
Transgenic animals treated with paracetamol were similar in
histopathology as observed with the vehicle treated controls (image
Figure 2. Time dependent changes in tumor growth of NDEA-treated c-Myc transgenic mice. (A) The organ and tumor volume was
assessed by CT and by histopathology. Depicted is the percentage tumor volume at different stages measured either by histopathology (light gray)
or by contrast enhanced CT imaging (dark gray). The mean diameter of lesions (B) and the total number of lesions (C) are shown. *p,0.05. **p,0.01.
doi:10.1371/journal.pone.0030432.g002
Figure 1. Contrast-enhanced CT and
18F-FDG-PET of the liver of an NDEA-treated c-Myc transgenic mouse. Axial slices of a CT (A) and
an FDG-PET scan (B) as well as coronal slices of a CT scan (C) and macroscopic view (D) of an explanted liver of an NDEA treated mouse at the age of 7
months. When compared to the normal liver parenchyma tumors are hypodens at CT as the uptake of the liver specific contrast agent is reduced. PET
scans reveal tumor lesions by an increased tracer uptake due to enhanced glucose metabolism. Because of the advanced stage of disease tumors of
different size had merged together. K=kidney, L=lung, S=spine, Sp=spleen, T=tumor.
doi:10.1371/journal.pone.0030432.g001
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saline treated transgenic animals displayed small foci of hepato-
cellular carcinoma. Here the cell size was smaller as compared to
the dysplastic foci with an increase in nuclear size and a significant
distortion of the architecture revealing multilayered trabecula and
areas of cystic pseudoglands.
The number, size and biological aggressiveness of liver lesions
were entirely linked to the NDEA treatment (Figure 6C).
Hepatocellular carcinoma with multilayered trabecular architec-
ture was observed as were pseudoglandular areas and sometimes
cystic spaces within tumors. Of the 18 animals examined by
histopathology 13 revealed hepatocellular carcinomas some of
which (n=10 animals) displayed dysplastic nodules adjacent to the
hepatocellular carcinoma as well. Furthermore, 3 animals were
identified with dysplastic nodules only while in 8 cases the HCC
was also accompanied by marked bile duct proliferation. All HCC
had areas of multilayered trabecular architecture, the majority also
revealed pseudoglandular areas sometimes with large cystic and
peliosis-like spaces. Due to the close spatial and temporal
relationship of dysplastic nodules and HCC in the livers of the
transgenic animals it seemed reasonable to define dysplastic
nodules as precursors and early lesions of liver cancer. Here, the
size of lesions may be used as a means to differentiate the liver
lesions whereby dysplastic nodules were smaller than 5 mm and
HCC were larger than 10 mm.
Some animals treated with NDEA displayed metastasis of the
primary liver cancer into lung (Figure 7B) but treatment with
NDEA also induced primary lung cancer as evidenced by in vivo
imaging and histopathology (Figure 7C). Thus, some animals were
burdened by primary and secondary tumor growth in two different
organs.
Accuracy of in vivo imaging
There was a highly significant correlation between the liver
volume, calculated by semiautomatic segmentation of CT-scans,
and the liver weight, determined ex vivo (correlation coefficient
r=0.99, p,0.001). Additionally the calculated liver volume
correlated with the estimated tumor volume (r=0.94, p,0.001)
(see Figure S2).
In Figure S3 liver to body weight ratio of transgenic mice
treated with either NDEA or BHT is given. When the tumor
volume determined by in vivo mCT and mPET imaging was
compared with the tumor area defined by histopathology, a
Table 2. Mean tumor volume for NDEA treated c-Myc
transgenic mice separated by gender.
4 months 5.5 months 7 months 8.5 months
Gender CT Histo CT Histo CT Histo* CT Histo
Male 0602 624 7 630 45619 46624 48617 68613 8060
Female 5652 3 618 65632 47623 50620 75607 4 607 3 63
Data were obtained by CT and histopathology and are defined as mean
percentage tumor volume and standard error of the mean for NDEA treated
animals. Data are broken down by gender. At the age of 5.5 months the tumor
incidence was 100% for male and female animals. No gender specific difference




Figure 3. Contrast-enhanced CT,
18F-FDG-PET and fused images of c-Myc transgenic mice treated with NDEA at the age of 5.5 and 7
months. (A) CT image demonstrates a single tumor lesion (A1) in a 5.5 months old mouse without increased
18F-FDG uptake (A2). The fused CT and
PET image is depicted in A3. (B) At the age of 7 months expansive tumor growth (B1) as well as an increased tracer uptake in hepatocellular
carcinoma (B2) is observed. The fused CT and PET image is depicted in B3. G=gallbladder, K=kidney, L=liver, S=spine, St=stomach, T=tumor.
doi:10.1371/journal.pone.0030432.g003
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strating the goodness of in vivo imaging (data not shown). Overall,
all animals, defined by histopathology as positive for hepatocellular
carcinoma, were accurately identified by in vivo imaging.
Discussion
More informative and cost-effective testing strategies are in
need to ensure protection of human health and the environment
from risks that can be posed by chemicals. So far, the two-year
rodent cancer bioassay is employed for hazard identification and
risk assessment but prediction of carcinogenicity represents a
problem which, as yet, could not be resolved satisfactorily
[27,28]. Much hope has been attached to the use of transgenic
animal models but several models tested so far failed to meet
expectations [9,11,29].
Here, we report findings with a c-Myc transgenic mouse
models that accurately predicts risk for hepatocellular carcino-
ma for the genotoxic carcinogen NDEA. This transgenic model
was evaluated in detail by histopathology and subjected to
advanced in vivo imaging techniques. Indeed, contrast-enhanced
mCT and
18F-FDG mPET metabolic imaging are facile methods
for the detection of liver lesions and can be considered as robust
in vivo imaging techniques to quantify lesions and to characterize
tumor morphology [18,19,30]. In the present study, liver and
tumor volume were quantified based on semiautomatic
segmentation of CT scans [17]. A good correlation between
t u m o rv o l u m em e a s u r e di nC Ta n dt u m o rl o a dd e t e r m i n e db y
histopathology was obtained. All animals, that displayed
hepatocellular carcinoma, were accurately detected by CT
and lesions as small as 1 mm in size could be defined. A notable
finding of the present study is the ability to distinguish between
dysplastic foci and tumor lesions by size, i.e. lesions ,5m m
typically represented dysplastic nodules of different grade
whereas hypodens lesions of .10 mm were hepatocellular
carcinomas. In order to detected small liver lesions in CT,
optimal contrast of the liver parenchyma is of crucial
importance [13,19]. This may not always be achieved. In the
present study 10 out of 60 animals failed to present sufficient
contrast and similar findings have been reported by others
[31,32]. Furthermore, high costs of the liver-specific contrast
agent still limit its wide use in preclinical studies. In this regard
PET imaging of
18F-FDG can be easily achieved and the radio-
labeled glucose can be injected intraperitoneally. Specifically,
18F-FDG-PET provided additional information about tumor
growth and differentiation as well as tumor necrosis and/or
other cavities where no uptake of glucose is possible due to cysts
within the tumor. Glucose uptake in tumors of $5m mw a s
statistically significantly chang e dw h e nc o m p a r e dw i t ht u m o r so f
.10 mm. Thus, for tumors of this size spillover and partial
volume effects are negligible and this agrees well with previous
findings [18]. However, an estimate of tumor-to-non tumor
ratio in tumors of ,5 mm can be confounded by spillover and
partial volume effects, which especially occur in very small
lesions and therefore the data needs to be viewed with caution
and corrected. Overall, 18F-FDG uptake was highly dependent
on the tumor size. Nonetheless, a definitive differentiation
between HCC and precursor lesio n ss u c ha sf o c io fl a r g ec e l l
dysplasia was not always possible, because some smaller HCCs
did not show increased FDG-uptake when compared to the
normal surrounding liver parenchyma (see Figure 4). Moreover,
it should be noted that FDG-uptake reflects glucose metabolism,
which is not necessarily specific for tumor infiltration. Indeed,
increased FDG-uptake has also been reported for inflammation.
Despite this limitation a further advantage of in vivo imaging is
the early detection of metastatic spread as well as growth of
independent secondary carcinoma as observed in the present study
whereby NDEA treated transgenic animals presented metastasiz-
ing liver cancer into lung but also displayed primary lung cancer
growth; note, other investigators reported similar metastatic
spread in a c-Myc and TGFa co-expressing transgenic mouse
model [11,33]. Thus, in vivo imaging offers the possibility to
examine different tissues and organs within the same data
acquisition.
The present study evidences the utility of mPET/mCT for
quantitative evaluation of hepatocellular carcinoma. Follow-up
examinations by serial and or sequential PET/CT scanning of the
same animal provided additional information about tumor growth
and development as well as metastatic spread and secondary
tumor growth. This genetic tumor model may thus become an
interesting preclinical testing strategy for liver carcinogens in an
evaluation of experimental drugs and chemicals as part of short-
term bioassays but studies with additional chemicals are needed to
affirm the validity of the model.
As a proof of concept the genotoxic carcinogen NDEA, the
weak tumor promoting agent BHT and the non-carcinogenic
hepatotoxin paracetamol were examined. While the c-Myc
transgenic model is genetically forced to develop hepatocellular
carcinoma it can be used to assay activity of prototypic chemicals.
It is of considerable importance that NDEA treatment of other
genetic models, such as the rasH2 and p53 deficient mice failed to
induce tumours within such a short period of time, i.e. 5.5 months
[34,35].
In the present study BHT, at the dose given, failed as a tumor
promoting agent and for this non-genotoxic tumour promoting
agent a threshold has been established. While some reports suggest
Figure 4.
18F-FDG uptake to determine the tumor-to-non-
tumor ratios in tumors of different size. Tumor-to-non-tumor
ratio, determined by PET glucose imaging, was significantly increased in
lesions .10 mm. *p,0.05. **p,0.01.
doi:10.1371/journal.pone.0030432.g004
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dependent sensitivity for this chemical had been observed [39].
Thus, several strains of mice failed to respond to the effects of
BHT even at high doses [36,40,41]. Possible BHT accelerates
tumour growth in the c-Myc transgenic model at later time points
or at higher doses. In the present investigation, however,
histopathology defined mainly dysplastic nodules for this study
group even at the age of 8.5 months.
In contrast, NDEA was effective in promoting carcinogenesis
and treatment with this chemical caused metastasis of primary
HCC into the lung as well as primary lung cancer growth
therefore demonstrating high plasticity of the c-Myc transgenic
model in some animals as early as the age of 5.5 months.
The effects of vehicle treatment were studied as well. None but
one animal aged 8.5 months of the saline transgenic controls had
tumors. A similar result was obtained when the mean diameter
of lesions was compared between the NDEA and the corn oil as
well as saline controls, i.e. approximately 9 mm for NDEA
versus 3 and 2 mm for the corn oil and saline controls,
respectively.
Because of its poor solubility in physiological saline NDEA was
dissolved in corn oil. Note, the corn oil vehicle moderately affected
Figure 5. Fused mPET/mCT images of the liver of c-Myc transgenic mice treated with physiological saline, BHT or NDEA. Depicted are
the liver morphology as determined by CT (A1, B1,C1), the glucose metabolism (A2, B2, C2) and fused PET and CT scans (A3, B3, C3) of transgenic
animals treated with either physiological saline (A), with BHT (B) or with NDEA (C) at the age of 8.5 months. Note, after treatment with NDEA
expansive tumor growth with large increase of liver weight and compression and displacement of adjacent organs was observed. Here, the lesions
showed an increased 18F-FDG uptake. In contrast, in corresponding control animals treated with physiological saline no liver lesions were observed.
After treatment with BHT small hypodens lesions are noticed, but PET did not show an increased 18F-FDG uptake. K=kidney, L=liver, S=spine,
Sp=spleen, St=stomach, T=tumor.
doi:10.1371/journal.pone.0030432.g005
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these CT findings primarily as foci of dysplastic nodules of
different grade. Furthermore, all mice treated with corn oil showed
fat accumulation in abdomen that may play role in tumor growth
or induction of inflammation. Note, in the technical report 426 of
the National Toxicology Program of the US corn oil was shown to
cause hyperplasia and adenoma of exocrine organs. Thus, corn oil
should be viewed with caution but treatment of the non-transgenic
controls with the vehicle helped to better define the effects elicited
by corn oil.
Finally, paracetamol treatment did not influence tumor growth
and thus served as a hepatotoxic but non-carcinogenic control.
Overall, the c-Myc transgenic mouse model is responsive to
the genotoxic carcinogen NDEA and may possibly differentiate
between safe and hazardous chemicals as evidenced by the
development of hepatocellular carcinoma already at the age of
5.5 months. The findings of the present study are also consistent
with observations obtained with NDEA treated c-met knock-out
mice where tumor growth was likewise accelerated [25].
Shortening the time of cancer bioassays will advance carcino-
genicity testing but further studies with several agents are
needed.
In conclusion, the combination of mCT and mPET imaging
allowed in vivo detection and quantification of hepatocellular
carcinoma. This proof of concept study provides evidence for the
utility of the c-Myc transgenic model in a short-term cancer
bioassay with the genotoxic agent NDEA. Validation of short term
cancer bioassay is a priority task and will require the study of
diverse chemicals with different mechanism of carcinogenicity.
Nonetheless, the application of in vivo imaging techniques will
significantly reduce the use of laboratory animals and likely enable
earlier detection of hazardous drugs and chemicals.
Figure 6. Histopathology of the liver of c-Myc treated transgenic animals. (A) Diffuse liver cell dysplasia of physiological saline (=vehicle)
treated transgenic mice at (A1) 50- and (A2) 200-fold magnification. (B) Large cell dysplasia of various degrees in BHT treated animals at (B1) 50- and
(B2) 200-fold magnification. (C) Hepatocellular carcinoma of a transgenic mouse treated with the genotoxic carcinogen NDEA at (C1) 50 and (C2) 200-
fold magnification.
doi:10.1371/journal.pone.0030432.g006
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Figure S1 Scheme of the gene construct for the produc-
tion of c-Myc transgenic mice. ( A )T h eg e n ec o n s t r u c t
contains the sequence of the a1-antitrypsine promoter thereby
enabling liver specific gene expression of c-Myc. Based on
ongoing research evidence was obtained that this genetic model
of liver cancer undergoes different stages of disease with initial
low and high grade dysplasia followed by different grades of
hepatocellular carcinoma as evidenced by histopathology. (B)
Depicted is an ethidium bromide stained agarose gel of a 303 bp
PCR amplification product of the transgene detected in
individual animals; the lanes 2, 3, 7, 10, 13, 15, and 16 refer
to non-transgenic animals (no band) while the lanes 4, 6, 8, 9,
11, 12, 14, 17, 18 and 19 are transgenic animals. Note, lane 20
is a mock (water) negative control. MW=molecular weight
marker.
(TIF)
Figure S2 Correlation between liver weight, liver vol-
ume and tumor volume of c-Myc transgenic mice. (A)
demonstrates the close correlation between the liver weight and
the liver volume (p,0.001, r=0.99). (B) The correlation between
liver volume and tumor volume – as determined by CT – is shown
(p,0.001, r=0.94).
(TIF)
Figure S3 Liver volume in BHT- and in NDEA-treated c-
Myc transgenic mice at different stages of disease. Liver
volume as determined by semiautomatic segmentation in contrast-
enhanced computed tomography was constant over time in BHT-
Figure 7. CT and histopathology of the lung of NDEA treated c-Myc transgenic mice. (A) Normal lung parenchyma of a vehicle treated
control animal as shown by CT (A1) and by histopathology (A2). CT of NDEA treated animals at the age of 8.5 months. Depicted are lung nodules of
different size (red arrows). Histopathology evidenced those lung nodules as metastasis of a poorly differentiated HCC (B2) and as well
adenocarcinoma of the lung (C2).
doi:10.1371/journal.pone.0030432.g007
In Vivo Imaging in Short-Term Cancer Bioassays
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30432treated animals (A), whereas in NDE-treated animals it increased
till the age of 8.5 months (B).
(TIF)
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